A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Verastem, Inc.
ALX Oncology Inc.
BicycleTx Limited
Centre Leon Berard
NiKang Therapeutics, Inc.
Pfizer
Pliant Therapeutics, Inc.
Eli Lilly and Company
AstraZeneca
MOMA Therapeutics
Eli Lilly and Company
Tongji Hospital
Tongji Hospital
Kivu Bioscience Inc.
University of California, San Francisco
M.D. Anderson Cancer Center
MOMA Therapeutics
Astellas Pharma Inc
Kestrel Therapeutics, Inc.
National Institutes of Health Clinical Center (CC)
University of Maryland, Baltimore
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Edwards Lifesciences
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eli Lilly and Company
7 Hills Pharma, LLC
National Cancer Institute (NCI)
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Plexium, Inc.
The Netherlands Cancer Institute
Beijing Biotech
Parabilis Medicines, Inc.
The Methodist Hospital Research Institute
Revolution Medicines, Inc.
Pfizer
USWM, LLC (dba US WorldMeds)
Coherus Oncology, Inc.
Lumos Pharma
Actuate Therapeutics Inc.
Conjupro Biotherapeutics, Inc.
Taiho Oncology, Inc.
Alterome Therapeutics, Inc.
IDEAYA Biosciences